ORIGINAL ARTICLES
IMAJ | volume 28
Journal 9, September 2026
pages: 572-577
Age-Period-Cohort Analysis of Creutzfeldt-Jakob Disease in Israel (1985–2019)
1 Department of Neurology, Kaplan Medical Center, Rehovot, Israel
2 Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
3 Department of Neurology, Barzilai Medical Center, Ashkelon, Israel
4 Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
5 Department of Neurology, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
6 Department of Physiology and Pharmacology, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
Summary
Background:
Although the epidemiology of Creutzfeldt-Jakob disease (CJD) in Israel has been studied extensively, it is unknown whether its incidence is mainly a result of vertical transmission due to the high penetrance of the E200K mutation in patients with familial CJD (f-CJD) compared to sporadic CJD (s-CJD), or whether there are other yet undiscovered contributing factors.
Objectives:
To conduct an age-period-cohort (APC) analysis of Creutzfeldt-Jakob disease in Israel.
Methods:
In this APC analysis, we used a web-based statistical tool to identify whether patient age, period of birth, and cohort had any effect on incidence trends of s-CJD and f-CJD.
Results:
APC analysis demonstrated no significant shifts in net drift, indicating the absence of any overall trend of changes over time. Cohort analysis revealed that individuals affected by either s-CJD or f-CJD who were mostly born in Israel in the second half of the 20th century exhibited the same risk as those born mainly in Libya at the beginning of 20th century. There were no changes in risk of s-CJD and f-CJD between 1985 and 2019.
Conclusions:
The incidence rates of s-CJD and f-CJD in Israel have remained unchanged, indicating that the probability of a future increase in the incidence is negligible.